previous studies have demonstrated some significant differences in hla allele frequencies in leukemic patients and normal subjects. we have analyzed hla class ii alleles and haplotypes in 60 iranian patients with acute myelogenous leukemia (aml) and 180 unrelated normal subjects. blood samples were collected after obtaining informed consents. from the patients and control dna extraction and hla...

Altered mRNA metabolism is a feature of many cancers including blast crisis chronic myelogenous leukemia. Indeed, loss of function of many tumor suppressors regulating cell proliferation, survival, and differentiation results from aberrant mRNA processing, nuclear export, and/or translation. Here, we summarize the effects of increased BCR/ABL oncogenic activity on the expression and function of...

G RANULOCYTE TRANSFUSIONS from donors with chronic myelogenous leukemia have been used with increasing frequency since this source of cells was first suggested by Morse in 1961.1,2,3,4 Prior to that time, all efforts in white cell transfusion had been ineffective because of the inadequate numbers of white cells available from normal donors, although the feasibility of such therapy had been show...

A quantitative radioimmunoassay has been developed for human dihydrofolate reductase (tetrahydrofolate dehydrogenase; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase, EC 1.5.1.3) by using antiserum raised in rabbits against the active enzyme purified from calf liver. An immunoreactive protein could be identified in the cytoplasm of chronic myelogenous leukemia cells, which contained no functional...

(1) Synthesis of deoxythymidine by either direct transfer of deoxyribosyl to thymine (pyrimidine deoxyribosyltransferase) or by a coupled deoxynucleoside phosphorylase mechanism is approximately twofold greater with normal leukocyte extracts (55 to 88% granulocytes) than with extracts prepared from leukocytes obtained from patients with chronic myelogenous leukemia. Activities in lymphocytes (n...

Over the last quarter century investigators have demonstrated that allogeneic hematopoietic cell transplantation (HCT) can cure chronic myelogenous leukemia (CML). Early reports suggested the efficacy of related donor transplant after a myeloablative preparative regimen containing total body irradiation (TBI) [1 /3]. Subsequent studies have identified variables which improve outcome such as tra...

A new and rare type of Bcr/Abl junction between exon C3 of the 3' portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an unusual breakpoint position on chromosome 22...

The antigenic phenotype of myelomonocytic progenitors [colony-forming unit granulocyte-macrophage (CFU-GM)] from 33 patients with chronic myeloproliferative disorders was investigated using four cytotoxic monoclonal antibodies. Monoclonal antibodies S3-13, S8-6, and S16-144 which recognize normal hemopoietic progenitors of different lineages reacted with almost all CFU-GM. R1B-19 monoclonal ant...

a retrospective study was done on 130 aml patients treated in shariati and imam hospitals in tehran from 1991 to 1997 to investigate the value of three post-remission methods of treatment. all patients who were in complete remission (cr) (group i) had been treated with ara-c (300 mg/m2/day continuous infusion for 5 days) and daunorubicine (45 mg/m2/day for 3 days) as induction and early consoli...